Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it will conduct a conference call
with investors to review the results of its Phase II exploratory NAFLD/NASH study with Namodenoson which achieved its primary and secondary efficacy endpoints, while showing continued safety.
Top-line results from the Phase II double-blind, placebo-controlled, dose-finding efficacy and safety study which enrolled 60 patients with non-alcoholic fatty liver disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH), were announced on April 7, 2020 and can be found here.
Call Information Date: Thursday, April 16, 2020
Time: 4:05 p.m. ET
Dial-in U.S.: 1-877-423-9813
Dial-in Israel: 1-201-689-8573
Conference ID: 13702174
Can-Fite CEO, Dr. Pnina Fishman will give an introduction, followed by a presentation of the data by the study’s Principal Investigator Dr. Rifaat Safadi, Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center, Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hebrew University in Israel. Commenting on the data will be Dr. Scott Friedman, a key opinion leader in NASH and Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York City. The next steps in the clinical development of Namodenoson for the treatment of NASH will be discussed. The presentation will be followed by a Q&A session.
The investor call will be accessible through the New/Events section of Can-Fite’s website at www.canfite.com where it will be archived for a period of time.